What the chart actually does

The category chart is a sorting tool. It takes a systolic number (the top number, the pressure when the heart beats) and a diastolic number (the bottom number, the pressure between beats) and assigns them to one of four bands: normal, elevated, stage 1, or stage 2. A separate article in this series walks through those bands and their exact cutoffs.

Two features of the chart are easy to miss. First, the guideline applies the categories to an average of two or more careful readings taken on two or more occasions, not to a single reading. Second, the categories describe blood pressure, not people. "Stage 1 hypertension" is a range of numbers. Whether you have the condition is a diagnosis, and a diagnosis depends on repeated measurements interpreted by a health care professional. The 2025 guideline recommends confirming a suspected diagnosis with readings taken outside the office, at home or with a wearable 24 hour monitor, and gives that recommendation its strongest grade.

The chart is genuinely useful. It gives you a shared vocabulary with your care team, and it tells you how seriously to take a set of readings. What it cannot do is tell you whether you need medicine, which medicine, or what number you and your health care professional should be aiming for. Those answers come from a second layer of information.

The second layer: your estimated risk

The 2025 guideline, published in August 2025, made a change that many people have not heard about. For readings in the stage 1 range, 130 to 139 systolic or 80 to 89 diastolic, the decision about medicine depends on a personal estimate of cardiovascular risk, not on the category alone.

The tool is called PREVENT, short for Predicting Risk of cardiovascular disease EVENTs. The American Heart Association developed it from records of more than 6.5 million adults and released it in 2023. It estimates the chance of a heart attack, stroke, or heart failure over the next 10 years for adults aged 30 to 79 who do not already have cardiovascular disease. Its inputs are age, sex, systolic blood pressure, total and HDL cholesterol, a kidney function measure, body mass index, diabetes status, smoking, and whether you already take blood pressure or cholesterol medicine. A ZIP code can be added as an optional input.

Here is how the guideline combines the risk estimate with the category, as summarized by the American Academy of Family Physicians:

1. 1 If your average is 140/90 mm Hg or higher, the stage 2 range, the guideline recommends medicine along with lifestyle changes regardless of the risk score.
2. 2 If your average is 130/80 mm Hg or higher and you have cardiovascular disease, a prior stroke, diabetes, chronic kidney disease, or a 10 year PREVENT risk of 7.5 percent or higher, the guideline recommends medicine along with lifestyle changes.
3. 3 If your average is 130/80 mm Hg or higher and your 10 year PREVENT risk is below 7.5 percent, the guideline recommends lifestyle changes first, and medicine if the average is still 130/80 or higher after 3 to 6 months.

Now return to the two people at 134/82. Suppose the first is 68, has type 2 diabetes, and has a PREVENT estimate of 12 percent. The second is 44, does not smoke, has favorable cholesterol numbers, and has an estimate of 3 percent. Same category, opposite sides of the 7.5 percent line, and therefore different starting points in the guideline. The 44 year old is likely to hear about a 3 to 6 month lifestyle trial and a follow up appointment. The 68 year old is likely to hear about medicine now, and also about lifestyle changes, since the guideline recommends both together.

Whether either path applies to you is a decision to make with your health care professional. The risk estimate is a population average applied to your inputs. A health care professional weighs it alongside things the calculator does not capture, such as family history, other illnesses, and what the readings look like at home.

Why different experts draw different lines

If you have ever compared two blood pressure charts and found they disagreed, you were not confused. They do disagree, and the disagreement extends to what number treatment should aim for.

1. 1 The 2025 AHA and ACC guideline sets a general treatment goal below 130/80 mm Hg for adults, with adjustments for people in institutional care, people with limited life expectancy, and pregnancy.
2. 2 The American Academy of Family Physicians, which represents family doctors, reviewed the 2025 guideline in October 2025 and gave it an "Affirmation of Value" rather than a full endorsement. One stated concern was that the universal goal below 130/80 does not match the academy's own guidance. The AAFP's 2022 target guideline strongly recommends treating adults with hypertension to below 140/90 mm Hg and says health care professionals may consider a lower target, below 135/85 mm Hg, to reduce heart attacks.
3. 3 The European Society of Cardiology's 2024 guideline defines hypertension at 140/90 mm Hg or higher, then asks health care professionals to aim for a systolic pressure of 120 to 129 mm Hg in people taking medicine, provided the treatment is well tolerated. It explicitly allows more lenient goals for people aged 85 and over, people with moderate to severe frailty or limited life expectancy, and people who get symptoms from low pressure on standing.
4. 4 KDIGO, the international kidney disease group, recommends a systolic target below 120 mm Hg for adults with chronic kidney disease and high blood pressure, but only when pressure is measured with a carefully standardized office technique.

These groups read the same trials. They differ on how to weigh benefit against harm and on how confident to be when applying trial results to everyday practice. The AAFP's own guideline shows the trade in plain numbers. Lower targets reduced heart attacks, from about 2.6 percent of people to about 1.8 percent over roughly 3.7 years, which works out to about 1 heart attack prevented for every 137 people treated to the lower goal. Lower targets also increased serious episodes of fainting and low blood pressure, from about 6.8 percent to about 9.8 percent, or roughly 1 extra serious episode for every 33 people. People in the lower target groups needed, on average, one additional medicine. Serious adverse events of all kinds combined were not significantly different between the groups.

Family doctors looked at that trade and chose a more conservative default. Cardiologists looked at the same numbers and chose a more aggressive one. Neither choice is wrong. They are different judgments about a real trade off, and the judgment that fits you depends on your own risk, how you tolerate medicines, and how many medicines you are willing to take.

What the big trial can and cannot tell you

Much of the push toward lower targets comes from one study, called SPRINT. It is worth understanding what it showed and whom it studied, because it explains both the guideline's ambition and the caution of its critics.

SPRINT enrolled 9,361 adults aged 50 and older with a systolic pressure of 130 mm Hg or higher and at least one additional risk factor, such as existing cardiovascular disease, chronic kidney disease, or age 75 or older. Half were treated toward a systolic goal below 120 mm Hg and half toward a goal below 140. The trial was stopped early, after a median of 3.26 years, because the benefit was already clear. Major cardiovascular events, a combined measure of heart attack, stroke, heart failure, and cardiovascular death, occurred at 1.65 percent per year in the intensive group and 2.19 percent per year in the standard group, a 25 percent relative reduction. Deaths from any cause fell by 27 percent in relative terms.

In absolute terms, that is roughly 5 fewer major events for every 1,000 people treated intensively for a year. The cost was more side effects. Serious episodes of low blood pressure occurred in 2.4 percent of the intensive group versus 1.4 percent of the standard group, fainting in 2.3 versus 1.7 percent, electrolyte problems in 3.1 versus 2.3 percent, and acute kidney injury in 4.1 versus 2.5 percent.

Now the part that matters for your own plan. SPRINT excluded people with diabetes and people who had a prior stroke. It excluded people with dementia and people living in nursing homes or assisted living. One analysis estimated that only 20 to 30 percent of people with high blood pressure resemble SPRINT participants. If you have diabetes, have had a stroke, or are frail, the trial that anchors the lower targets did not include people like you. This does not mean lower targets are wrong for you. It means the evidence is being extended beyond the people it was gathered from, and that extension is a judgment your health care professional makes, not something a chart can do.

Later trials have tested lower targets in some of the groups SPRINT left out. A Chinese trial called STEP enrolled 8,511 adults aged 60 to 80 and found a 26 percent relative reduction in cardiovascular events with a systolic goal of 110 to 130 mm Hg compared with 130 to 150. The evidence is growing, but it still does not cover everyone, and the people it covers least well are often the people with the most complicated health.

The number depends on how it was measured

There is a quieter reason a chart cannot set your plan. The same person produces different numbers depending on how the pressure is measured, and the trials behind the targets used unusually careful methods.

SPRINT used automated office measurement. The person sat quietly while a machine took several readings at one minute intervals and averaged them. The European guideline notes that this technique tracks closely with 24 hour ambulatory monitoring and tends to reduce the white coat effect, the rise in pressure that many people show in a medical setting. A single reading taken over a sleeve at the end of a hurried intake is a different measurement, and it usually runs higher.

How much higher is not a small matter. In a study of 38,260 adults with high blood pressure in one primary care system, simply repeating the measurement during the same visit lowered the systolic reading by a median of 8 mm Hg, and 36 percent of the repeated readings ended up below 140/90. KDIGO, the kidney group with the strictest target, says plainly that the relationship between a routine office reading and a standardized one is so variable that no correction factor can convert one into the other. Its target of below 120 systolic applies only to standardized readings.

This is why "below 120" on a chart and "below 120" in a kidney specialist's plan are not the same number, and why comparing your quick pharmacy reading with a trial target can mislead you in either direction. It is also why the 2025 guideline treats home and office readings as related but not identical. An office reading of 140/90 mm Hg corresponds to roughly 135/85 at home, and an office 160/100 to about 145/90 at home. A separate article in this series explains home, office, and ambulatory measurement in more detail.

Reasons a clinician may aim higher than the chart suggests

Charts point in one direction: lower is better. Real plans sometimes move the other way, on purpose.

Orthostatic hypotension is the most common reason. It is a drop in blood pressure on standing, defined as a fall of 20 mm Hg or more in the systolic number or 10 mm Hg or more in the diastolic number within a few minutes of getting up. Blood pressure treatment itself can contribute to it. The European guideline says everyone should be assessed for it at the initial visit and again whenever symptoms suggest it, and it names symptomatic orthostatic hypotension as a reason to accept a more lenient goal. If your seated reading is 128/78 but you feel faint when you stand, a health care professional may reasonably decide that pushing the seated number lower is the wrong aim. Dizziness on standing is worth reporting promptly. Do not change or skip a dose on your own. Ask your health care professional to check your pressure sitting and standing and to review the plan with you.

Frailty, advanced age, and limited life expectancy are the other reasons the guidelines name. The European guideline sets its lenient category at age 85 and over or moderate to severe frailty, and describes the goal in those cases as a pressure that is as low as reasonably achievable rather than a fixed number. The 2025 United States guideline names institutional care and limited life expectancy as reasons to adjust its general goal. Falls, long medicine lists, kidney function, and personal preference all enter these decisions. None of them appear on a chart.

Where the chart still gives a clear instruction

There is one place where the chart does tell you what to do without a health care professional's input, and it is at the top. If a reading is 180/120 mm Hg or higher, wait at least a minute and take it again. If it is still that high and you have chest pain, shortness of breath, back pain, numbness or weakness, a change in vision, or difficulty speaking, call 911 and do not wait to see whether it comes down. If it is still that high and you have none of those symptoms, you likely have severe hypertension, which usually does not require a hospital, but you should contact your health care professional as soon as possible. That instruction is the same for everyone because the danger it addresses does not depend on a risk score.

Everywhere else on the chart, the category tells you what to raise with your care team and how soon. It does not tell you what to take.

How to use the chart well

1. 1 Read your category from an average of properly taken readings, not from a single number. The measurement rules matter as much as the chart.
2. 2 Ask what your 10 year PREVENT risk is, or ask your health care professional to estimate it with you. For readings in the stage 1 range, that number is doing as much work as the category.
3. 3 Ask which target your care team is using for you and which guideline it comes from. A goal below 130/80 mm Hg, below 140/90, or a systolic in the 120s are all defensible answers, for different people and different reasons. A separate article in this series suggests questions to ask about your personal target.
4. 4 Mention anything that might argue for a gentler goal: dizziness on standing, falls, a long medicine list, kidney disease, or simply being over 80.
5. 5 Bring your home readings and your monitor to appointments so your health care professional can judge them against the office number rather than guessing which one to believe.